checkAd

    DGAP-News  516  0 Kommentare MOLOGEN AG: First combination trial with MGN1703 and a checkpoint inhibitor in collaboration with MD Anderson

    DGAP-News: MOLOGEN AG / Key word(s): Alliance/Study
    MOLOGEN AG: First combination trial with MGN1703 and a checkpoint inhibitor
    in collaboration with MD Anderson

    19.01.2016 / 08:09
    The issuer is solely responsible for the content of this announcement.

    ---------------------------------------------------------------------------

    PRESS RELEASE N 1 / 2016 of 01/19/2016

    MOLOGEN AG: First combination trial with MGN1703 and a checkpoint inhibitor
    in collaboration with MD Anderson

    Berlin, 19 January 2016 - The biotech company MOLOGEN AG (ISIN
    DE0006637200; Frankfurt Stock Exchange Prime Standard: MGN) today announced
    that it has entered into a collaboration agreement with The University of
    Texas MD Anderson Cancer Center (MD Anderson). The agreement relates to a
    phase I trial with MOLOGEN's immunomodulator lefitolimod (MGN1703) in
    combination with the immunotherapy Yervoy(R) (ipilimumab) in patients with
    advanced solid malignancies. This is the first time that lefitolimod
    (MGN1703) will be evaluated in combination with a checkpoint inhibitor.
    Should MGN1703 succeed in augmenting the efficacy of immune checkpoint
    blockade, the potential applications of the compound could be broadened.
    This study has been initiated based on the idea that the combination of
    these two immunotherapies could have synergistic effects by a broader
    activation of the immune system.

    The aim of the study titled "A Phase I Trial of Ipilimumab (Immunotherapy)
    and MGN1703 (TLR Agonist) in Patients with Advanced Solid Malignancies" is
    to initially find the highest tolerable dose of lefitolimod (MGN1703) that
    can be given in combination with Yervoy(R) (ipilimumab) to patients with
    advanced tumors. The safety of this drug combination will also be studied.
    Furthermore, this trial aims to evaluate the efficacy of the combination of
    these two therapies in an expansion phase. The combination of a TLR9
    agonist and a checkpoint inhibitor is of particular interest: lefitolimod
    (MGN1703) broadly activates the immune system and enables it to fight
    cancer. Yervoy(R), manufactured by Bristol-Myers Squibb Co., is a
    recombinant, human monoclonal antibody and immune checkpoint inhibitor
    approved to treat patients with unresectable or metastatic melanoma.

    "We are excited about the opportunity to study this combination. Our hope
    is not only to define a safe dose but understand if the combination will
    have activity and further understand the underlying biology of these
    drugs", said Dr. David S. Hong, Deputy Chair and Associate Professor,
    Department of Investigational Cancer Therapeutics, Division of Cancer
    Medicine, MD Anderson Cancer Center, and principal investigator of the
    Seite 1 von 3


    EQS Group AG
    0 Follower
    Autor folgen

    Verfasst von EQS Group AG
    DGAP-News MOLOGEN AG: First combination trial with MGN1703 and a checkpoint inhibitor in collaboration with MD Anderson DGAP-News: MOLOGEN AG / Key word(s): Alliance/Study MOLOGEN AG: First combination trial with MGN1703 and a checkpoint inhibitor in collaboration with MD Anderson 19.01.2016 / 08:09 The issuer is solely responsible for the content of this …